PAL-335
| Clinical data | |
|---|---|
| Other names | PAL335 |
| Drug class | Selective serotonin releasing agent (SSRA) |
| ATC code |
|
PAL-335 is a selective serotonin releasing agent (SSRA) which has been used in scientific research.[1][2] It has been found to increase reward responsiveness (a prohedonic effect) in rodents similarly to the serotonin–norepinephrine–dopamine releasing agent and entactogen MDMA and the norepinephrine–dopamine releasing agent and stimulant 3-methylamphetamine (3-MA; PAL-314).[1][2] The drug has also been found to impair task performance similarly to MDMA but unlike 3-MA.[1][2] The interoceptive effects of PAL-335 in drug discrimination studies are being assessed.[1][2] PAL-335 was first described in the scientific literature by Bruce E. Blough and colleagues in 2026.[1] It is being used as a tool to help study the mechanisms underlying the rewarding effects and misuse liability of MDMA.[1][2] The chemical structure of PAL-335 does not yet appear to have been disclosed.[1][2]
See also
References
- ^ a b c d e f g Bloom N, LaMalfa KS, Blough BE, Kangas B (2026). "Toward a Comprehensive Profile of MDMA as a Candidate Therapeutic: The Role of the Dopamine-Serotonin Continuum in Prohedonic Efficacy and Abuse Liability (Abstract ID: 228563)". The Journal of Pharmacology and Experimental Therapeutics. 393 (5) 104268. doi:10.1016/j.jpet.2026.104268.
- ^ a b c d e f Bloom NB, LaMalfa KS, Blough BE, Kangas BD (2026). Optimizing MDMA: Neurochemical Mechanisms Underlying Prohedonic Efficacy and Abuse Potential (PDF). 2026 Behavior, Biology, and Chemistry (BBC): Translational Research in Substance Use Disorders. p. 19.